MRSN Stock Summary and Trading Ideas (Mersana Therapeutics | NASDAQ:MRSN)

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Mersana Therapeutics trades on the NASDAQ stock market under the symbol MRSN.

As of January 16, 2026, MRSN stock price was flat at $29.08 with million shares trading.

MRSN has a beta of 0.80, meaning it tends to be less sensitive to market movements. MRSN has a correlation of 0.01 to the broad based SPY ETF.

MRSN has a market cap of $145.36 million. This is considered a Micro Cap stock.

Last quarter Mersana Therapeutics reported $11 million in Revenue and -$1.51 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.40.

In the last 3 years, MRSN traded as high as $240.50 and as low as $5.21.

The top ETF exchange traded funds that MRSN belongs to (by Net Assets): VTI, VXF.

MRSN has outperformed the market in the last year with a return of +89.3%, while the SPY ETF gained +18.1%. In the last 3 month period, MRSN beat the market returning +176.0%, while SPY returned +5.0%. However, in the most recent 2 weeks MRSN has underperformed the stock market by returning +0.1%, while SPY returned +1.2%.

MRSN support price is $28.68 and resistance is $29.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRSN shares will trade within this expected range on the day.